Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Operating Margin: 2016-2024

Historic Operating Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -31.51%.

  • Akebia Therapeutics' Operating Margin rose 4098.00% to 7.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.88%, marking a year-over-year decrease of 22809.00%. This contributed to the annual value of -31.51% for FY2024, which is 43105.00% up from last year.
  • Per Akebia Therapeutics' latest filing, its Operating Margin stood at -31.51% for FY2024, which was up 93.19% from -462.56% recorded in FY2023.
  • Akebia Therapeutics' Operating Margin's 5-year high stood at -27.62% during FY2022, with a 5-year trough of -462.56% in FY2023.
  • In the last 3 years, Akebia Therapeutics' Operating Margin had a median value of -31.51% in 2024 and averaged -173.90%.
  • As far as peak fluctuations go, Akebia Therapeutics' Operating Margin spiked by 273,465bps in 2020, and later tumbled by 43,494bps in 2023.
  • Yearly analysis of 5 years shows Akebia Therapeutics' Operating Margin stood at -128.23% in 2020, then skyrocketed by 326bps to -124.97% in 2021, then spiked by 9,735bps to -27.62% in 2022, then tumbled by 43,494bps to -462.56% in 2023, then surged by 43,105bps to -31.51% in 2024.